3 Reasons to Buy Bristol Myers Squibb Stock

Bristol Myers Squibb faces a major patent cliff, with Eliquis and Opdivo accounting for more than $24.4 billion in sales and U.S. exclusivity expiring in 2028. The article argues the company can offset this with a 50-compound pipeline, 10 planned new medicines by decade-end, and growing products such as Camzyos (+97% YoY to $314 million), Breyanzi (+56% to $411 million), and Reblozyl (+16% to $555 million). Investors are also paid to wait with a 4.6% dividend yield that is only 40% of 2026 earnings estimates, while the stock trades at 8.5x 2026 earnings.

Analysis

BMY is being priced like a slow-motion ex-growth utility, but the market may be underestimating how much optionality is embedded in the next 18-24 months. The key second-order effect is that a successful pipeline reset would not just replace lost revenue; it would mechanically rerate the equity because the current multiple already assumes a low-visibility, low-growth terminal profile. That asymmetry is what matters: the stock does not need a perfect execution story, only enough proof that the post-cliff earnings base is stabilizing to force multiple compression risk out of the shares.

The most important catalyst is not the broad pipeline narrative, but binary de-risking events around a small number of assets. A positive readout in the psychiatric extension of Cobenfy would change the company’s category from “defensive income name” to “platform with launch velocity,” while a failure likely keeps the stock rangebound rather than impaired, because the dividend and current earnings base buy time. That makes the near-term setup closer to a funded call option than a classic value trap, provided management continues converting growth assets faster than legacy erosion accelerates.

Competition is the hidden issue. Any successful replacement of Eliquis economics via Milvexian would still face a harsher payer and formulary environment than the original wave of blockbuster launches, so the bar for true offset is higher than headline sales comparisons suggest. Meanwhile, stronger BMY execution would likely pressure other large-cap pharma names with weaker pipelines and similar income-investor ownership, as capital rotates toward the one name with a visible path to self-help plus yield.

The contrarian takeaway is that consensus may be overfocusing on the patent cliff date and underweighting the fact that markets usually rerate this kind of name before the cliff is fully visible in the numbers. If the next one or two catalysts land, the stock can move on sentiment long before any true revenue replacement is complete. The risk is that multiple disappointments leave the dividend intact but trap capital for years, so the trade should be structured around catalyst windows rather than passive ownership.

Key Decisions for Investors

• Long BMY common into catalyst windows over the next 3-6 months; target a low-double-digit total return if pipeline news reduces cliff anxiety, with the dividend providing carry while waiting.
• Buy BMY Jan-2027 call spreads to express rerating upside without full downside exposure; attractive if you believe one positive clinical readout can lift the multiple from depressed single digits.
• Pair trade: long BMY / short a lower-quality large-cap pharma with weaker pipeline visibility and similar income ownership; seek relative outperformance if investors rotate toward self-help plus yield.
• If Cobenfy psychosis data disappoints, use any post-event selloff to add only if the dividend remains covered and management guidance on the growth portfolio holds; otherwise cap losses quickly since the thesis becomes mostly income-only.